Socially Adept: Pharma Companies Must Proactively Gauge Risk Tolerance For Online Promotions, Experts Advise
This article was originally published in The Pink Sheet Daily
Executive Summary
Absent formal FDA guidance, pharmaceutical manufacturers must decide how much risk they are willing to take with Internet and social media product promotion and be capable of walking away from certain online venues, panelists say at the FDLI annual meeting.
You may also be interested in...
Drug Safety Communications Are Not Crisis Management Tools, FDA Says
A new draft guidance explains the Center for Drug Evaluation and Research’s approach to communicating emerging drug safety information. Since 2010, Drug Safety Communications have replaced a variety of audience-focused tools laid out in a 2007 guidance, but FDA says public health alerts will be used to communicate about products that pose an immediate danger.
FDA Proposals For Studying Internet Promotions Raise Concerns
FDA should not delay draft guidance on Internet and social media promotional activities while it studies how consumer understanding of a drug’s safety and efficacy is affected by the techniques used to present information on branded websites, according to comments on the proposed studies.
FDA Proposals For Studying Internet Promotions Raise Concerns
FDA should not delay draft guidance on Internet and social media promotional activities while it studies how consumer understanding of a drug’s safety and efficacy is affected by the techniques used to present information on branded websites, according to comments on the proposed studies.